Thema: US22053A1079
QNCX, US22053A1079
stock-6687228_1920.jpg - Foto: THN
IRulya Therapeutics stock sharpens focus on LAM-001 pipeline
IRulya Therapeutics stock is moving into a pulmonary-focused phase after Quince Therapeutics completed its corporate rebrand. LAM-001 remains the lead program.
ad-hoc-news.de, heute 02:13 Uhr
QNCX, US22053A1079
IRulya schedules October 22 conference: what it means for ...
IRulya posted October 19 data showing 81.30 m in six patients. IRulya Therapeutics stock now centers on 3 Phase 2 programs and USD 116 million cash.
ad-hoc-news.de, 21.10.26 05:00 Uhr
QNCX, US22053A1079
IRulya schedules October 22 conference: ticker for Quince ...
Cash stood at USD 116 million on June 30, 2026. Quince Therapeutics stock enters a new phase with LAM-001 studies.
ad-hoc-news.de, 16.10.26 00:22 Uhr
QNCX, US22053A1079
Quince Therapeutics relaunched as IRulya: Raymond James ...
Cash stood at USD 116 million on June 30, 2026. For QNCX stock, BOS data are expected in the first quarter of 2027.
ad-hoc-news.de, 14.10.26 02:18 Uhr
QNCX, US22053A1079
Quince Therapeutics stock faces October 6 vote after board ...
Quince Therapeutics stock was trading at USD 28.995 on October 5, with a special vote scheduled for October 6. Q2 brought a USD 75.5 million loss.
ad-hoc-news.de, 05.10.26 22:36 Uhr
Quince, Therapeutics
Quince Therapeutics Explores Strategic Alternatives After ...
